+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07210047

Evaluation of HuL001 Combined With Lenalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma Patients

Led by HuniLife Biotechnology, Inc. · Updated on 2026-09-18

21

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of the antibody drug HuL001 with Lenalidomide and Dexamethasone to treat adults with relapsed or refractory Multiple Myeloma. This study aims to assess both the safety and tolerability as well as the effectiveness of this therapeutic combination in patients who have had prior treatments. The trial includes a dose escalation phase followed by a dose expansion phase to determine appropriate dosing levels. Participants will receive HuL001 antibody injections every two weeks. They will also take Lenalidomide daily for 21 consecutive days each month and Dexamethasone once every week. The study includes a dose escalation phase with increasing doses of HuL001 and a dose expansion phase at the recommended dose. Throughout the treatment period, participants will visit the clinic on scheduled days for checkups and tests. During the study, participants will be closely monitored through clinical assessments, symptom diaries, and evaluations of their Myeloma response using established criteria. Researchers will track disease responses such as complete and partial remission and observe safety parameters including treatment-related adverse events. The treatment period and outcome assessments last up to eight months, with ongoing monitoring to evaluate immunogenicity and other safety factors.

CONDITIONS

Brief Title

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

Research Team

Z

Zoe Chan, master

M

Maisie Huang, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here